ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.27
-0.42%
US Tech 100
21,544.00
1.52%
S&P 500
6,083.53
0.54%
US Dollar vs CAD
1.42403
0.10%
Bitcoin
106,509.18
2.08%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. OS Therapies Incorporated (OSTX)

  7. OS Therapies Incorporated (OSTX) News

OSTX

OS Therapies (OSTX)

OS Therapies Incorporated
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:OSTX
DateTimeSourceHeadlineSymbolCompany
11/15/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
11/15/20248:47AMBusiness WireOS Therapies Reports Third Quarter 2024 Financial Results and Provides Business UpdateAMEX:OSTXOS Therapies Incorporated
11/15/20248:14AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:OSTXOS Therapies Incorporated
11/14/20243:58PMEdgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBAMEX:OSTXOS Therapies Incorporated
11/04/20246:00AMBusiness WireOS Therapies to Present at The Spartan Capital Investor ConferenceAMEX:OSTXOS Therapies Incorporated
11/01/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
10/30/20247:51AMBusiness WireJoin OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30AMEX:OSTXOS Therapies Incorporated
10/29/20243:10PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
10/28/20243:55PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
10/28/20243:44PMBusiness WireOS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of DirectorsAMEX:OSTXOS Therapies Incorporated
10/24/20247:46AMBusiness WireOS Therapies to Present at the LD Micro Main Event XVIIAMEX:OSTXOS Therapies Incorporated
10/17/20248:22AMBusiness WireOS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitAMEX:OSTXOS Therapies Incorporated
10/03/20247:00AMBusiness WireOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient VisitAMEX:OSTXOS Therapies Incorporated
09/13/20247:09AMBusiness WireOS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic CandidatesAMEX:OSTXOS Therapies Incorporated
09/05/20247:22AMBusiness WireOS Therapies to Present at H.C. Wainright 26th Annual Global Investment ConferenceAMEX:OSTXOS Therapies Incorporated
08/29/20246:53AMBusiness WireOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment DoseAMEX:OSTXOS Therapies Incorporated
08/22/20247:00AMBusiness WireOS Therapies Appoints Borys Shor, PhD to ADC Advisory BoardAMEX:OSTXOS Therapies Incorporated
08/22/20245:00AMBusiness WireOS Therapies Clarifies CUSIP of Common StockAMEX:OSTXOS Therapies Incorporated
08/19/20247:30AMBusiness WireOS Therapies Accepted Into Johnson & Johnson Innovation - JLABSAMEX:OSTXOS Therapies Incorporated
08/02/20247:55AMBusiness WireOS Therapies Forms Osteosarcoma Patient Advocacy Advisory BoardAMEX:OSTXOS Therapies Incorporated
08/01/20248:19AMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
08/01/20248:16AMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
08/01/20248:11AMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
08/01/20248:10AMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
08/01/20248:08AMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
07/31/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:OSTXOS Therapies Incorporated
07/31/20245:21PMBusiness WireOS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”AMEX:OSTXOS Therapies Incorporated
07/30/20241:41PMEdgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingAMEX:OSTXOS Therapies Incorporated
07/30/20241:29PMEdgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]AMEX:OSTXOS Therapies Incorporated
07/24/20249:48AMBusiness WireOS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast CancerAMEX:OSTXOS Therapies Incorporated
 Showing the most relevant articles for your search:AMEX:OSTX

Your Recent History

NASDAQ
TNXP
Tonix Pharmaceuticals
USOTC
MONI
Moon Equity (PK)
USOTC
ICTY
Eyecity Com (PK)
USOTC
FLCX
flooidCX (CE)
NASDAQ
AMRN
Amarin
USOTC
NBRI
North Bay Resources (PK)
USOTC
XERI
Xeriant (QB)
USOTC
ASII
Accredited Solutions (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
NASDAQ
TSLA
Tesla
USOTC
RNVA
Rennova Health (CE)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
CBRF
CyberFuels (PK)
USOTC
BCDS
BlaqClouds (PK)
NASDAQ
COOP
Mr Cooper
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved